Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery

[1]  M. Johannsen,et al.  The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. , 2010, The Journal of urology.

[2]  F. D. De Braud,et al.  The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. , 2010, European journal of cancer.

[3]  C. Verpelli,et al.  Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma , 2010, British Journal of Cancer.

[4]  K. Alitalo,et al.  How do angiopoietins Tie in with vascular endothelial growth factors? , 2010, Current opinion in hematology.

[5]  H. Kosmehl,et al.  A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies , 2010, Histochemistry and Cell Biology.

[6]  L. Zardi,et al.  Impact of VEGF‐dependent tumour micro‐environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice , 2009, The Journal of pathology.

[7]  H. Moch,et al.  Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response , 2009, Oncogene.

[8]  S. Niland,et al.  The extracellular matrix of blood vessels. , 2009, Current pharmaceutical design.

[9]  Sophie Astrof,et al.  Fibronectins in vascular morphogenesis , 2009, Angiogenesis.

[10]  D. Neri,et al.  Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy , 2008, Clinical Cancer Research.

[11]  A. Villa,et al.  A high‐affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo‐vasculature in vivo , 2008, International journal of cancer.

[12]  M. Nishisaka,et al.  Inhibition of angiogenesis by a tenascin-c peptide which is capable of activating beta1-integrins. , 2008, Biological & pharmaceutical bulletin.

[13]  Denis Wirtz,et al.  Fibronectin fibrillogenesis regulates three-dimensional neovessel formation. , 2008, Genes & development.

[14]  A. Buck,et al.  Human Antibody Against C Domain of Tenascin-C Visualizes Murine Atherosclerotic Plaques Ex Vivo , 2007, Journal of Nuclear Medicine.

[15]  R. Chiquet‐Ehrismann,et al.  Tenascin-C induced signaling in cancer. , 2006, Cancer letters.

[16]  Alfred Buck,et al.  Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. , 2006, Protein engineering, design & selection : PEDS.

[17]  M. Oya,et al.  Renal cancer cells lacking hypoxia inducible factor (HIF)-1α expression maintain vascular endothelial growth factor expression through HIF-2α , 2006 .

[18]  Dianbin Yang,et al.  Von Hippel–Lindau Gene Mutation in Non‐Syndromic Familial Pheochromocytomas , 2006, Annals of the New York Academy of Sciences.

[19]  S. Brack,et al.  Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder , 2006, Journal of Cancer Research and Clinical Oncology.

[20]  Dario Neri,et al.  Tumor-Targeting Properties of Novel Antibodies Specific to the Large Isoform of Tenascin-C , 2006, Clinical Cancer Research.

[21]  J. Edelberg,et al.  Vascular tenascin‐C regulates cardiac endothelial phenotype and neovascularization , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  G. Giannelli,et al.  Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. , 2005, Gastroenterology.

[23]  Roy Bicknell,et al.  Tumour vascular targeting , 2005, Nature Reviews Cancer.

[24]  Dario Neri,et al.  Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  Jeffrey C. Allen,et al.  Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. , 2002, Cancer research.

[26]  H. Kosmehl,et al.  Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. , 2002, Blood.

[27]  E. Werner,et al.  l-Ascorbic Acid Potentiates Endothelial Nitric Oxide Synthesis via a Chemical Stabilization of Tetrahydrobiopterin* , 2001, The Journal of Biological Chemistry.

[28]  P. Schirmacher,et al.  VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. , 2000, Cancer research.

[29]  H. Kosmehl,et al.  Synthesis and protein distribution of the unspliced large tenascin‐C isoform in oral squamous cell carcinoma , 1999, The Journal of pathology.

[30]  S. Schenk,et al.  The fibrinogen globe of tenascin-C promotes basic fibroblast growth factor-induced endothelial cell elongation. , 1999, Molecular biology of the cell.

[31]  J. Thompson,et al.  RT-PCR investigation of fibronectin mRNA isoforms in malignant, normal and reactive oral mucosa. , 1997, Oral oncology.

[32]  L. Zardi,et al.  Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues , 1992, International journal of cancer.

[33]  J. Schwarzbauer.  Alternative splicing of fibronectin: Three variants, three functions , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

[34]  I. Fidler,et al.  Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. , 1986, Cancer research.

[35]  D. Neri,et al.  Antibody-based vascular tumor targeting. , 2010, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[36]  M. Oya,et al.  Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. , 2007, Carcinogenesis.